Biodexa Pharmaceuticals (BDRX) Return on Sales (2015 - 2021)

Biodexa Pharmaceuticals (BDRX) has 5 years of Return on Sales data on file, last reported at 0.16% in Q4 2021.

• For the quarter ending Q4 2021, Return on Sales rose 2992.0% year-over-year to 0.16%; the trailing twelve-month figure through Dec 2021 stood at 0.53% (down 9.0% YoY), and the FY2023 full-year result was 0.21%, down 7.0% from the prior year.
• Return on Sales climbed to 0.16% in Q4 2021, from 30.08% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.04% in Q4 2019 to a low of 30.08% in Q4 2020.
• A 3-year average of 13.29% and a median of 11.52% in 2020 frame the typical range for Return on Sales.
• Across the five-year window, Return on Sales plunged 3004 bps in 2020 and soared 2992 bps in 2021, its largest moves.
• Tracing BDRX's Return on Sales over 3 years: stood at 0.04% in 2019, then tumbled by 72962 bps to 30.08% in 2020, then soared by 99 bps to 0.16% in 2021.
• Business Quant data shows BDRX's Return on Sales at 0.16% in Q4 2021, 30.08% in Q4 2020, and 22.87% in Q3 2020.